Fintel reports that on January 10, 2025, Roth MKM initiated coverage of Reviva Pharmaceuticals Holdings (NasdaqCM:RVPH) with a Buy recommendation.
Analyst Price Forecast Suggests 729.09% Upside
As of December 23, 2024, the average one-year price target for Reviva Pharmaceuticals Holdings is $15.50/share. The forecasts range from a low of $14.14 to a high of $17.85. The average price target represents an increase of 729.09% from its latest reported closing price of $1.87 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Reviva Pharmaceuticals Holdings is 0MM. The projected annual non-GAAP EPS is -0.90.
What is the Fund Sentiment?
There are 50 funds or institutions reporting positions in Reviva Pharmaceuticals Holdings. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to RVPH is 0.01%, an increase of 45.73%. Total shares owned by institutions increased in the last three months by 44.73% to 10,227K shares. 
The put/call ratio of RVPH is 0.14, indicating a bullish outlook.
What are Other Shareholders Doing?
Armistice Capital holds 3,186K shares representing 9.53% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
Millennium Management holds 1,833K shares representing 5.48% ownership of the company. In its prior filing, the firm reported owning 1,241K shares , representing an increase of 32.26%. The firm increased its portfolio allocation in RVPH by 70.06% over the last quarter.
Schonfeld Strategic Advisors holds 1,516K shares representing 4.53% ownership of the company. In its prior filing, the firm reported owning 1,014K shares , representing an increase of 33.12%. The firm increased its portfolio allocation in RVPH by 74.00% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 700K shares representing 2.09% ownership of the company. No change in the last quarter.
Woodline Partners holds 685K shares representing 2.05% ownership of the company. In its prior filing, the firm reported owning 1,593K shares , representing a decrease of 132.59%. The firm decreased its portfolio allocation in RVPH by 57.32% over the last quarter.
Reviva Pharmaceuticals Holdings Background Information
(This description is provided by the company.)
Reviva Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Reviva's primary focus is developing its lead product candidate, RP5063 (brilaroxazine), for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Reviva also intends to develop RP5063 for treating PAH and IPF. RP5063 is a serotonin, dopamine, and nicotinic receptor active compound, which has successfully completed a global Phase 2 clinical trial and has shown clinical efficacy and safety for schizophrenia and schizoaffective disorder.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
